financetom
Business
financetom
/
Business
/
Food retailer George Weston's Q3 revenue slightly misses estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Food retailer George Weston's Q3 revenue slightly misses estimates
Nov 14, 2025 4:20 AM

Overview

* George Weston Q3 revenue grows 4.6% yr/yr, slightly missing analyst expectations

* Adjusted EPS for Q3 beats consensus, reflecting strong operational performance

* Company completed a three-for-one stock split, enhancing share liquidity

Outlook

* George Weston expects adjusted net earnings to increase in 2025

* Loblaw expects full-year adjusted EPS growth in low double-digits

* Choice Properties raises 2025 FFO per unit outlook to C$1.06-C$1.07

Result Drivers

* LOBLAW PERFORMANCE - Loblaw's focus on value, convenience, and new store openings drove customer engagement and sales growth

* CHOICE PROPERTIES DEMAND - Strong tenant demand in grocery-anchored retail and industrial assets boosted Choice Properties' performance

* FAIR VALUE ADJUSTMENT - Positive impact on net earnings from fair value adjustment of Trust Unit liability due to Choice Properties unit price increase

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Slight C$19.55 C$19.59

Revenue Miss* bln bln (2

Analysts

)

Q3 Beat C$1.37 C$1.31

Adjusted (5

EPS Analysts

)

Q3 EPS C$1.23

Q3 C$2.34

Adjusted bln

EBITDA

Q3 12.00%

Adjusted

EBITDA

Margin

Q3 C$1.64

Operatin bln

g Income

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the food retail & distribution peer group is "buy"

* Wall Street's median 12-month price target for George Weston Ltd ( WNGRF ) is C$101.67, about 11.3% above its November 13 closing price of C$90.13

* The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 19 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Telefonica SA, H.I.G. Among Avatel Telecom's Suitors, Bloomberg Says
Telefonica SA, H.I.G. Among Avatel Telecom's Suitors, Bloomberg Says
May 17, 2024
01:46 PM EDT, 05/17/2024 (MT Newswires) -- Telefonica SA ( TEF ) and H.I.G. Capital are among the suitors considering bids for Spain's Avatel Telecom, Bloomberg reported Friday, citing people with knowledge of the matter. Price: 4.46, Change: +0.03, Percent Change: +0.68 ...
Salesforce First Quarter Likely Has Fewer Catalysts to be Excited About, Morgan Stanley Says
Salesforce First Quarter Likely Has Fewer Catalysts to be Excited About, Morgan Stanley Says
May 17, 2024
01:49 PM EDT, 05/17/2024 (MT Newswires) -- Salesforce ( CRM ) likely has fewer catalysts heading into fiscal first-quarter results despite stable demand, though the software maker appears to be in a solid position ahead of generative artificial intelligence product adoption in the medium term, Morgan Stanley said Friday. The company is scheduled to release first-quarter results May 29. Morgan...
(OFFICIAL)-UPDATE 3-US FDA approves Amgen drug for small cell lung cancer
(OFFICIAL)-UPDATE 3-US FDA approves Amgen drug for small cell lung cancer
May 17, 2024
(Amgen ( AMGN ) correction to pricing estimate in paragraph 4) May 16 (Reuters) - The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's ( AMGN ) tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small cell lung cancer that has worsened despite chemotherapy. The drug, marketed under the name Imdelltra, is...
Sector Update: Consumer
Sector Update: Consumer
May 17, 2024
01:34 PM EDT, 05/17/2024 (MT Newswires) -- Consumer stocks were mixed Friday afternoon, with the Consumer Staples Select Sector SPDR Fund (XLP) decreasing 0.2% and the Consumer Discretionary Select Sector SPDR Fund (XLY) adding 0.2%. In corporate news, GameStop ( GME ) shares tumbled 25% after reporting preliminary results that pointed to a sharp year-over-year decline in fiscal Q1 sales,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved